• Alumis reported topline results from its Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus.
• The study missed its main and key secondary goals in the overall patient population, weakening broad-label prospects in SLE.
• A prespecified high-interferon subgroup showed clear clinical benefit, supporting plans for Phase 3 regulatory discussions focused on that segment.
• The drug was generally well tolerated with no new safety concerns flagged.
• Management reiterated plans to file an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609010730PRIMZONEFULLFEED9819223) on September 01, 2026, and is solely responsible for the information contained therein.